Perturbation-based proteomic correlation profiling as a novel target deconvolution methodology
Ontology highlight
ABSTRACT:
ORGANISM(S): Homo Sapiens (human)
SUBMITTER: Kazuishi Kubota
PROVIDER: PXD008086 | JPOST Repository | Wed Jul 10 00:00:00 BST 2019
REPOSITORIES: jPOST
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| E16012921.raw | Raw | |||
| E16012922.raw | Raw | |||
| E16012924.raw | Raw | |||
| E16012925.raw | Raw | |||
| E16012941.raw | Raw |
Items per page: 5 1 - 5 of 20 |
Publications
Perturbation-Based Proteomic Correlation Profiling as a Target Deconvolution Methodology.
Ohki Yu Y Sakurai Hidetaka H Hoshino Madoka M Terashima Hideki H Shimizu Hiroki H Ishikawa Tomio T Ogiyama Tomoko T Muramatsu Yasunori Y Nakanishi Toshiyuki T Miyazaki Shojiro S Tsuruoka Hiroyuki H Kobayashi Hideki H Kubota Kazuishi K
Cell chemical biology 20181115 1
Molecular target identification of small molecules, so-called target deconvolution, is a major obstacle to phenotype-based drug discovery. Here, we developed an approach called perturbation-based proteomic correlation profiling (PPCP) utilizing the correlation between protein quantity and binding activity of compounds under cellular perturbation by gene silencing and successfully identified lanosterol synthase as a molecular target of TGF-β pathway inhibitor. This PPCP concept was extended to th ...[more]
Similar Datasets
Project description:A new approach of proteomic correlation profiling named "PPCP" was developed based on previous proteomic correlation profiling approach. This data is used as proteome profiling of cell lines for cell line-based PPCP.
2019-07-10 | PXD010350 | JPOST Repository
Project description:Ribosome profiling is a widespread tool for studying translational dynamics in human cells. Its central assumption is that ribosome footprint density on a transcript quantitatively reflects protein synthesis. Here, we test this assumption using pulsed-SILAC (pSILAC) high-accuracy targeted proteomics. We focus on multiple myeloma cells exposed to bortezomib, a first-line chemotherapy and proteasome inhibitor. In the absence of drug effects, we found that direct measurement of protein synthesis by pSILAC correlated well with indirect measurement of synthesis from ribosome footprint density. This correlation, however, broke down under bortezomib-induced stress. By developing a statistical model integrating longitudinal proteomic and mRNA-seq measurements, we found that proteomics could directly detect global alterations in translational rate caused by bortezomib; these changes are not detectable by ribosomal profiling alone. Further, by incorporating pSILAC data into a gene expression model, we predict cell-stress specific proteome remodeling events. These results demonstrate that pSILAC provides an important complement to ribosome profiling in measuring proteome dynamics.
2017-05-18 | GSE69047 | GEO
Project description:Food safety evaluation of new, genetically modified (GM) plant varieties has led to basic questions regarding the safety assessment of new plant varieties and whole foods derived thereof. An important part of the hazard identification in the European approach is a targeted compositional analysis of new GM plant varieties compared to one or more conventional reference varieties. Comparative analysis will become much more informative with unbiased analytical approaches, such as omics profiling. Analysis tools that estimate the similarity of new varieties to the reference would in turn greatly facilitate hazard identification. Further in-depth biological, functional and eventually toxicological analysis of the data would then only be necessary for varieties that fall outside the scale of those with a history of safe human consumption. For this purpose, the use of a one-class classifier tool was explored in this study to assess and classify transcriptome profiles of potato varieties. Five potato varieties were grown in the Netherlands during the same year (NL samples) and included four biological replicates for four varieties or two biological replicates for the fifth one. They were all analysed in 2011. A sixth variety was grown in the UK in a previous study and a previous year, for which the data are submitted in E-MTAB-605. The two UK samples were analysed in the original study in 2008 and again together with the NL samples in the present study, resulting in four profiles for two samples.
2014-03-04 | E-MTAB-1707 | biostudies-arrayexpress
Project description:IgA nephropathy (IgAN) is the most common glomerulonephritis in the world. The disease is characterized by galactose deficient IgA (gd-IgA) in the circulation forming immune complexes. The complexes are deposited in the glomerular mesangium leading to inflammation and loss of renal function, but the pathophysiology of the disease is still not fully understood. Using an integrated global transcriptomic and proteomic profiling approach we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsies from patients with IgAN. The influence of galactose deficient IgA (gd-IgA) on mesangial cells was investigated by proteomic profiling. By utilizing the previous published literature curated glomerular cell type-specific genes, we found that mesangial cells and their positive standard genes play a more dominant role in IgAN comparing to the podocyte standard genes. Additionally, the patient clinical parameters (serum creatinine values and estimated glomerular filtration rate - eGFR) significantly correlate with z-scores derived from expression profile of mesangial cell positive standard genes. 22 common pathways were identified both from in vivo microarray data and in vitro mesangial cell mass spectrometry data and the main part was inflammatory pathways. The correlation between clinical data and mesangial standard genes allows for a better understanding of the onset of IgAN. The genes, proteins and their corresponding pathways identified in this paper give us novel insights into the pathophysiological mechanisms leading to progression of IgAN.
2017-07-03 | GSE93798 | GEO
Project description:Ribosome profiling is a widespread tool for studying translational dynamics in human cells. Its central assumption is that ribosome footprint density on a transcript quantitatively reflects protein synthesis. Here, we test this assumption using pulsed-SILAC (pSILAC) high-accuracy targeted proteomics. We focus on multiple myeloma cells exposed to bortezomib, a first-line chemotherapy and proteasome inhibitor. In the absence of drug effects, we found that direct measurement of protein synthesis by pSILAC correlated well with indirect measurement of synthesis from ribosome footprint density. This correlation, however, broke down under bortezomib-induced stress. By developing a statistical model integrating longitudinal proteomic and mRNA-seq measurements, we found that proteomics could directly detect global alterations in translational rate caused by bortezomib; these changes are not detectable by ribosomal profiling alone. Further, by incorporating pSILAC data into a gene expression model, we predict cell-stress specific proteome remodeling events. These results demonstrate that pSILAC provides an important complement to ribosome profiling in measuring proteome dynamics. Timecourse experiment with six points over 48hr after bortezomib exposure in MM.1S myeloma cells. mRNA-seq and ribosome profiling data at each time point.
2017-05-18 | E-GEOD-69047 | biostudies-arrayexpress
Project description:IgA nephropathy (IgAN) is the most common glomerulonephritis in the world. The disease is characterized by galactose deficient IgA (gd-IgA) in the circulation forming immune complexes. The complexes are deposited in the glomerular mesangium leading to inflammation and loss of renal function, but the pathophysiology of the disease is still not fully understood. Using an integrated global transcriptomic and proteomic profiling approach we investigated the role of the mesangium in the onset and progression of IgAN. Global gene expression was investigated by microarray analysis of the glomerular compartment of renal biopsies from patients with IgAN. The influence of galactose deficient IgA (gd-IgA) on mesangial cells was investigated by proteomic profiling. By utilizing the previous published literature curated glomerular cell type-specific genes, we found that mesangial cells and their positive standard genes play a more dominant role in IgAN comparing to the podocyte standard genes. Additionally, the patient clinical parameters (serum creatinine values and estimated glomerular filtration rate - eGFR) significantly correlate with z-scores derived from expression profile of mesangial cell positive standard genes. 22 common pathways were identified both from in vivo microarray data and in vitro mesangial cell mass spectrometry data and the main part was inflammatory pathways. The correlation between clinical data and mesangial standard genes allows for a better understanding of the onset of IgAN. The genes, proteins and their corresponding pathways identified in this paper give us novel insights into the pathophysiological mechanisms leading to progression of IgAN. RNA from glomerular compartment was extracted and processed for hybridization on Affymetrix microarrays. This dataset is part of the TransQST collection.
2017-07-03 | E-GEOD-93798 | biostudies-arrayexpress
Project description:Here we describe a bead-based method capable of profiling tyrosine kinase phosphorylations in a multiplexed, high-throughput and low-cost manner. This approach allows for the discovery of tyrosine kinase-activating events, even when the DNA sequence is wild-type. In an effort to pilot the establishment of a tyrosine kinase activation catalog, we profiled tyrosine phosphorylation levels of 62 tyrosine kinases in 130 human cancer lines, and followed-up on the frequent SRC phosphorylation in glioblastoma. Keywords: quantitative measurements of tyrosine phosphorylation levels on tyrosine kinases
2008-12-05 | GSE13808 | GEO
Project description:Ngo D, Sinha S, Shen D, Kuhn E, Keyes M, Shi X, Benson M, O'Sullivan J, Keshishian H, Farrell L, Fifer MA, Vasan RS, Sabatine M, Larson MG, Carr SA, Wang TJ, Gerszten RE. Circulation 2016. Emerging proteomic technologies are beginning to permit the systematic characterization of human plasma samples. DNA-aptamer based technologies may address limitations of existing proteomic techniques, including low sample throughput, which have prevented proteomic analyses of large cohorts. We applied an aptamer-based proteomic technology that measures 1,129 proteins to identify potential novel biomarkers of cardiovascular disease. We found very early markers of myocardial injury in a robust, clinically-relevant perturbational model of planned myocardial injury, patients undergoing septal ablation for hypertrophic cardiomyopathy. We then tested whether the platform could detect novel associations between proteins and cardiovascular risk factors in individuals without overt cardiovascular disease using archived samples from the Framingham Heart Study. Further, we developed a new workflow integrating DNA-based immunoaffinity with mass spectrometry to analytically validate the specificity of aptamer findings. Our results highlight an emerging proteomics tool capable of profiling over one thousand low abundance analytes with high sensitivity and high precision, applicable both to well-phenotyped perturbational studies as well as large human cohorts.
2016-07-14 | MSV000079908 | MassIVE
Project description:Obesity-induced ectopic fat disposition in the liver is a major risk factor in the pathogenesis of type 2 diabetes as it impairs hepatic insulin sensitivity, a crucial component of whole body glucose homeostasis; however molecular mechanisms remain largely elusive. Understanding the pathogenesis of fatty liver, including the identification of novel genetic regulators that are involved in the regulation of liver metabolism under excess energy supply, is crucial for the development and implementation of efficient prevention and treatment strategies. We here developed a new method to integrate metabolomics and transcriptomics data based on pairwise correlation analysis of metabolites coupled to partial correlation combining the metabolite correlations with the transcript expression profiles followed by the construction of undirected, weighted graphs.This Correlation based Network Integration (CoNI) approach was applied to liver metabolome and transcriptome datasets of lean and HFD-fed obese mice to unravel previously hidden local regulator genes (LRG). The selected candidate genes were validated by transcriptome-proteome correlation analysis, by association studies with liver lipid metabolism in humans and by analysis of cellular metabolite levels after siRNA knockdown. Overall, the new bioinformatic CoNI approach for Omics datasets allowed us to identify genes regulating metabolic networks in livers of obese mice that if solely analyzing the transcriptome dataset would have remained hidden.
2021-07-09 | GSE137923 | GEO
Project description:The potency and selectivity of a small molecule inhibitor are key parameters to assess during the early stages of drug discovery. In particular, it is very informative for characterizing compounds in a relevant cellular context in order to reveal potential off-target effects and drug efficacy. Activity-based probes (ABPs) are valuable tools for that purpose, however, obtaining cellular target engagement data in a high-throughput format has been particularly challenging. Here, we describe a new methodology named ABPP-HT (high-throughput-compatible activity-based protein profiling), implementing a semi-automated proteomic sample preparation workflow that increased the throughput capabilities of the classical ABPP workflow approximately ten times while preserving its enzyme profiling characteristics. Using a panel of deubiquitylating enzyme (DUB) inhibitors, we demonstrate the feasibility of ABPP-HT to provide compound selectivity profiles of endogenous DUBs in a cellular context at a fraction of time as compared to previous methodologies
2021-02-24 | PXD023036 | Pride